Home News Healthcare

Tokyo Stock Exchange-listed Nitto Denko's research arm launches device to detect chronic kidney diseases early

Amala Balakrishner
Amala Balakrishner12/21/2020 10:35 AM GMT+08  • 2 min read
Tokyo Stock Exchange-listed Nitto Denko's research arm launches device to detect chronic kidney diseases early
Chronic kidney diseases can soon be detected early with the help of ACT by Zensorium, a device that is undergoing testing at SGH.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Chronic kidney diseases can soon be detected early with the help of ACT by Zensorium, a device that is undergoing testing at the Singapore General Hospital.

Offered by the Nitto Denko Asia Technical Centre (NAT), the research and development arm of the Tokyo Stock Exchange-listed Nitto Denko, the device works by testing a patient’s urine sample for increased levels of albumin and creatinine.

Albumin is a protein produced by the liver while creatinine is a waste product created from the wear and tear of muscles. High levels of these, correlates to a higher risk of a patient having chronic kidney disease.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now